0001437749-23-030955.txt : 20231108 0001437749-23-030955.hdr.sgml : 20231108 20231108161425 ACCESSION NUMBER: 0001437749-23-030955 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231108 DATE AS OF CHANGE: 20231108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACELRX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001427925 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35068 FILM NUMBER: 231388022 BUSINESS ADDRESS: STREET 1: 1850 GATEWAY DRIVE STREET 2: SUITE 175 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: 650-216-3500 MAIL ADDRESS: STREET 1: 1850 GATEWAY DRIVE STREET 2: SUITE 175 CITY: SAN MATEO STATE: CA ZIP: 94404 8-K 1 acrx20231107_8k.htm FORM 8-K acrx20231107_8k.htm
false 0001427925 0001427925 2023-11-08 2023-11-08
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 8, 2023
 
ACELRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
         
Delaware
  
001-35068
  
41-2193603
(State of incorporation)
  
(Commission File No.)
  
(IRS Employer Identification No.)
 
25821 Industrial Boulevard, Suite 400
Hayward, CA 94545
(Address of principal executive offices and zip code)
 
Registrant’s telephone number, including area code: (650) 216-3500
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
ACRX
The Nasdaq Global Market
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 2.02         Results of Operations and Financial Condition
 
On November 8, 2023, AcelRx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2023 and providing a corporate update (the “Release”). A copy of the Release is furnished herewith as Exhibit 99.1.
 
The information contained in this Item 2.02 and in Exhibit 99.1 shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in Exhibit 99.1 shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
 
 
Item 9.01         Financial Statements and Exhibits
 
Exhibit No.
Description
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
1
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: November 8, 2023
ACELRX PHARMACEUTICALS, INC.
By:
/s/ Raffi Asadorian
Raffi Asadorian
Chief Financial Officer
 
2
EX-99.1 2 ex_593215.htm EXHIBIT 99.1 ex_593215.htm

Exhibit 99.1

 

logo01.jpg

 

 

AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update

 

 

Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter

 

Company plans to begin its Niyad registrational study this quarter with topline data expected mid-2024

 

Cash and investments of $13.4 million as of September 30, 2023

 

Financing closed in July led by new healthcare investors providing up to $26.3 million, of which $10 million was made immediately available

 

Key Opinion Leader panel discussion on Niyad planned for December 6th

 

Webcast and conference call to be held today at 4:30 p.m. ET

 

 

SAN MATEO, Calif., November 8, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter 2023 financial results and provided a corporate update.

 

“We continue to advance our lead product candidate Niyad™, that has FDA Breakthrough Device designation, by prioritizing our resources to achieve regulatory and development milestones on this asset,” said Vince Angotti, Chief Executive Officer of AcelRx.  “Importantly, at the close of the third quarter, we received IDE approval from the FDA to proceed with the Niyad NEPHRO CRRT Study. NEPHRO stands for Nafamostat Efficacy in Phase 3 Registrational Continuous Renal Replacement Therapy Study. The NEPHRO study is set to start this quarter with top-line data expected by mid-2024 and submission of an application for Premarket Approval, or PMA, planned in the second half of next year. Niyad would be the first-ever U.S. approved regional anticoagulant for use in a dialysis circuit.”

 

 
 

 

“In addition, we have a Key Opinion Leader panel discussion that we will host on December 6th featuring nephrology and critical care experts where we plan to discuss the results from our market research, as well as the NEPHRO Study,” continued Angotti.

 

The NEPHRO Study, which recently received central Institutional Review Board (IRB) approval, is designed as a prospective, double-blinded trial to be conducted at up to 10 U.S. hospital intensive care units. The study will enroll and evaluate 166 adult patients undergoing renal replacement therapy, who cannot tolerate heparin or are at risk for bleeding. The primary endpoint of the study is mean post-filter activated clotting time using Niyad versus placebo over the first 24 hours. Key secondary endpoints include filter lifespan, number of filter changes over 72 hours, number of transfusions over 72 hours and dialysis efficacy (based on urea concentration) over the first 24 hours.

 

2023 Third Quarter and Recent Corporate Highlights

 

 

●

In October, AcelRx announced the approval of an Investigational Device Exemption (IDE) submission to the United States Food and Drug Administration (FDA) allowing the Company to advance Niyad into a registrational study. This study will evaluate the safety and efficacy of Niyad to support a PMA application expected to be submitted to the FDA in the second half of 2024.

 

 

●

In July, AcelRx announced a private placement of common stock, pre-funded warrants and common warrants for aggregate gross proceeds to the Company of $10 million, before deducting the placement agent’s fees and other offering expenses payable by the Company, with an additional potential $16.3 million upon the exercise of common warrants, which include an acceleration feature should the Company achieve certain performance milestones. This financing provides up to $26.3 million in gross proceeds upon the exercise of milestone-affected warrants. The private placement was priced "at-the-market" under the rules and regulations of The Nasdaq Stock Market LLC.  The private placement was led by new investors including Nantahala Capital Management and closed on July 21, 2023.

 

Third Quarter 2023 Financial Information

 

 

●

The cash and cash equivalents balance was $13.4 million as of September 30, 2023. The senior debt with Oxford was fully repaid in the second quarter of 2023.

 

 

●

Revenues of $0.1 million for the third quarter primarily represent the royalty revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the prior period are included within the net loss from discontinued operations line item of the Statement of Operations.

 

 
 

 

 

●

Combined R&D and SG&A expenses for the third quarter of 2023 totaled $3.4 million compared to $4.5 million for the third quarter of 2022. Excluding non-cash stock-based compensation expense, these amounts were $3.0 million for the third quarter of 2023, compared to $3.9 million for the third quarter of 2022. The decrease in combined R&D and SG&A expenses in the third quarter of 2023 was primarily due to a reduction in headcount partially offset by an increase in Niyad-related research and development costs.

 

 

●

The divestment of DSUVIA represents a discontinued operation; accordingly, all historical operating results for the business are reflected within discontinued operations. For the three months ended September 30, 2023, the Company recognized net loss from continuing operations of $1.4 million. For the three months ended September 30, 2022, the Company recognized a net loss from continuing operations of $4.6 million.

 

 

●

Net loss attributable to common shareholders for the third quarter of 2023 was $1.4 million, or $0.08 per basic and diluted share, compared to a net loss of $6.9 million, or $0.94 per basic and diluted share, for the third quarter of 2022.

 

 

Conference Call and Webcast Information

 

AcelRx will host a live webcast and conference call today, Wednesday, November 8, 2023 at 4:30 p.m. Eastern Standard Time/1:30 p.m. Pacific Standard Time to discuss the results and provide an update on the Company’s business.

 

The webcast can be accessed here or by visiting the Investors section of the Company's website at www.acelrx.com and clicking on the webcast link within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the AcelRx website for 90 days following the event.

 

Investors who wish to participate in the conference call may do so by dialing 1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian callers, or 1-412-902-4204 (toll applies) for international callers. The conference ID is 10182244.

 

 

About Nafamostat

 

Nafamostat is a broad spectrum, synthetic serine protease inhibitor with anticoagulant, anti-inflammatory and potential anti-viral activities. Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. LTX-608 is a proprietary nafamostat formulation for direct IV infusion that will be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC) and acute pancreatitis.

 

 
 

 

About AcelRx Pharmaceuticals, Inc.

 

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. AcelRx is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. This release is intended for investors only. For additional information about AcelRx, please visit www.acelrx.com.

 

 

Forward-looking statements

 

This press release contains forward-looking statements based upon AcelRx's current expectations. These and any other forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "potential," "believe," "expect," "expects," "expected," "anticipate," "may," "will," "enable," "should," "seek," "approximately," "intends," "intended," "plans," "planned," "planning," "estimates," "benefits," or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans or intentions may also include forward-looking statements, which are predictions, projections and other statements about future events that are based on current expectations and assumptions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied by such statements, including: (i) risks relating to AcelRx's product development activities and ongoing commercial business operations; (ii) risks related to the ability of AcelRx and its business partners to implement development plans, launch plans, forecasts and other business expectations; (iii) risks related to unexpected variations in market growth and demand for AcelRx's commercial and developmental products and technologies; (iv) risks related to AcelRx's liquidity and our ability to maintain capital resources sufficient to conduct the clinical studies required for our developmental products; (v) risks related to AcelRx's ability to retain its listing on the Nasdaq exchange; (vi) risks related to the ability of AcelRx to successfully design and conduct safe, effective and timely clinical studies for our developmental products; and (vii) risks relating to AcelRx’s ability to fund, seek and obtain regulatory approvals for our developmental product candidates. Although it is not possible to predict or identify all such risks and uncertainties, they may include, but are not limited to, those described under the caption "Risk Factors" and elsewhere in AcelRx's annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the Securities and Exchange Commission (SEC) and any subsequent public filings. You are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date such statements were first made. To the degree financial information is included in this press release, it is in summary form only and must be considered in the context of the full details provided in AcelRx's most recent annual, quarterly or current report as filed or furnished with the SEC. AcelRx's SEC reports are available at www.acelrx.com under the "Investors" tab. Except to the extent required by law, AcelRx undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect new information, events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

 

 

 

Investor Contacts:

 

AcelRx

Raffi Asadorian, CFO

650-216-3500

investors@acelrx.com

 

LifeSci Advisors

Kevin Gardner

617-283-2856

kgardner@lifesciadvisors.com

 

Chris Calabrese

917-680-5608

ccalabrese@lifesciadvisors.com

 

 

### 

 

 
 

 

Selected Financial Data

(in thousands, except per share data)

(unaudited)

 

   

Three Months Ended

 
   

September 30

  
   

2023

    

2022

  

Statement of Comprehensive Income (Loss) Data

                
                 

Royalty revenue

   $ 117     $ -  

Operating costs and expenses:

                

Research and development (1)

     1,178       799  

Selling, general and administrative (1)

     2,248       3,724  

Impairment of property and equipment

     -       -  

Total operating costs and expenses

     3,426       4,523  

Loss from operations

     (3,309 )     (4,523 )

Other income (expense):

                

Interest expense

     -       (245 )

Interest income and other income (expense), net

     1,893       140  

Non-cash interest income on liability related to sale of future royalties

     -       -  

Gain on extinguishment of liability related to sale of future royalties

     -       -  

Total other income (expense)

     1,893       (105 )

Net income (loss) before income taxes

     (1,416 )     (4,628 )

Provision for income taxes

     (2 )     (11 )

Net income (loss) from continuing operations

     (1,418 )     (4,639 )

Net income (loss) from discontinued operations

     61       (2,111 )

Net income (loss)

     (1,357 )     (6,750 )

Deemed dividends related to Series A Redeemable Convertible Preferred Stock

     -       (186 )

Income allocated to participating securities

     -       -  

Net income (loss) attributable to Common Shareholders, basic

   $ (1,357 )   $ (6,936 )

Net income (loss) attributable to Common Shareholders, diluted

   $ (1,357 )   $ (6,936 )

Net income (loss) per share attributable to stockholders:

          

Basic earnings (loss) per share

                

Income (loss) from continuing operations

   $ (0.08 )   $ (0.65 )

Income (loss) from discontinued operations

   $ 0.00     $ (0.29 )

Net income (loss)

   $ (0.08 )   $ (0.94 )

Diluted earnings (loss) per share

                

Income (loss) from continuing operations

   $ (0.08 )   $ (0.65 )

Income (loss) from discontinued operations

   $ 0.00     $ (0.29 )

Net income (loss)

   $ (0.08 )   $ (0.94 )
                 

Shares used in computing net income (loss) per share of common stock, basic

     16,758       7,377  
                 

Shares used in computing net income (loss) per share of common stock, diluted

     16,758       7,377  
                 

(1) Includes the following non-cash stock-based compensation expense:

                

Research and development

   $ 210     $ 139  

Selling, general and administrative

     168       519  

Discontinued operations

     -       43  

Total

   $ 378     $ 701  

 

 
 

 

Selected Balance Sheet Data

(in thousands)

 

   

September 30, 2023

    

December 31, 2022(1)

  
   

(Unaudited)

          

Cash, cash equivalents, restricted cash and investments

   $ 13,389     $ 20,770  

Total assets

     23,261       47,487  

Total liabilities

     4,954       25,673  

Total stockholders' equity

     18,307       21,814  

 

(1) Derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

 

 

 

Reconciliation of Non-GAAP Financial Measures

(Operating Expenses less stock-based compensation expense)

 

   

Three Months Ended

 
   

September 30

  
   

2023

    

2022

  
                 

Operating expenses (GAAP):

                

Research and development

   $ 1,178     $ 799  

General and administrative

     2,248       3,724  

Total operating expenses

     3,426       4,523  

Less stock-based compensation expense

     378       658  

Operating expenses (non-GAAP)

   $ 3,048     $ 3,865  

 

 
 EX-101.SCH 3 acrx-20231108.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 acrx-20231108_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 acrx-20231108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 acrx-20231108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 logo01.jpg begin 644 logo01.jpg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

M72?LA6Z"!LL@XQNV@X&:.4#[JKX9_P""M?['.M?M.WNC7WB+XM>'? 7P^T5A M'8V%Y9R,)KUU8O-(P(/$'FSQCLJM%""1])Y/R->ED^;8G+<4L7A&E-7LVD[7[735_,\O.,GPV9X M9X/&)N$K72;C>W=IIVOT,_\ X)L?\$D]+_8B\7:EXMUC6[7Q=XFN8OL^F7,= MH8(M-A8?O"H8D^8^<%N,+D#[QS]F5\N?&CXT_%#QO^U9?_#KX:WVAZ7#X?TB M.^O;B]AW[G;:=N>V \> /4FL+X*_ME>-D_9E^)WBCQ1)IM]J/@^[:SL)HH=D M(>+QL^:;LNBT6R26B7IZ[AD^2X/*\,L'@8KW;;NV_7IILC[ HKYK_9A;X[>-K[PSXD\3^(/#K>%=2A^UW%G#:[;ED9# ML7/0')4_05]*5Y;T/4"BBBD!X1%^S'K6I?MUW?Q+U*;39M!M]+6PTZ#<6G0B M(*=RD8QN>8\'T]:]2^*7A.Z\2?#'7M*T=;>WO]2LI;>!F^1 [*0"2![UTM%. MX'RSX@_8D\23_L1Z'\,K&\TI=2AO$N=1F>1A"XWLS!3MR>HZ@9Q5C]IW]COQ MIX\^)/@KQ-X)U30;2;PEI:Z?';ZE#YL88%_G"E65LAL8(XP#]/IZBGS,#YK_ M &>/V2/&/PWD^(GB;Q#JVB7WC/QE8FTMQ90>3:VV(R 2%4 9;9PJX 3/)-)H M?['GB+PQ^P3=?#&SNM-7Q!?+()YQ(RVY+RY/S;<_ZL*.G45]*T42@QC&[N2*D\!?LC>)-./QHN=3U33X= M1^)7G0VH1>8L1.X%@-K*FQ0RRX7"?,L:GK@DYSQ7TA11S= /C_7/V/?C-X5^*7Q U;P9XL\.6NG^/ M)V:Z:ZAW3F(F3:H)1MA42N,J?0]A6MXE_8*UN']C/PY\,=)U/3FO+?5TU+5K MJ0M'%.-TCLJ GAC&!GJ$[9KZJHHYF!XC\>_V:M7^*/Q ^%\MC<6$7A[P3=B MYNXIB?,EVA50( ,?=!ZD5Q/Q5_9;^+-I^TOK7C[X?^)?#NGOK%HEJ1?P>8\: M*!\N&1AU'45]244N8#YJ_:C_ &5_B!\;]!^'5]9ZYH3>)O![&XNVNX/]&N;@ M^6=X0*5(#)]TK@@TG[-/[)7C7P7\;M8^(GCC5M U#79]).F6-OIMJ((8\E#Y MC!54# C"X Y#,2>E?2U%/F=K ?,?PC_98^(7P9_9M\1:'H^H>&U\8>(-9>^E MN+B/[1:F!@@9&5T(8G#]5Q\U8?P4_87\::5\>-%\:>-M1\)K#X=1G@MM#T]; M?SWP<;E1%'&\L6LYH MX$8C?Y; ,J-Q@$^)_[8G@3QQ]JL(_#GA& ;X&=O/>4-(^0N M,)O#M[I=KI8M-)BL[15,$JC:C.0BD@ #N XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Nov. 08, 2023
Document Information [Line Items]  
Entity, Registrant Name ACELRX PHARMACEUTICALS, INC.
Document, Type 8-K
Document, Period End Date Nov. 08, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-35068
Entity, Tax Identification Number 41-2193603
Entity, Address, Address Line One 25821 Industrial Boulevard, Suite 400
Entity, Address, City or Town Hayward
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94545
City Area Code 650
Local Phone Number 216-3500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ACRX
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001427925

XML 9 acrx20231107_8k_htm.xml IDEA: XBRL DOCUMENT 0001427925 2023-11-08 2023-11-08 false 0001427925 8-K 2023-11-08 ACELRX PHARMACEUTICALS, INC. DE 001-35068 41-2193603 25821 Industrial Boulevard, Suite 400 Hayward CA 94545 650 216-3500 false false false false Common Stock ACRX NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.acrx.com/20231108/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports acrx-20231108.xsd acrx-20231108_def.xml acrx-20231108_lab.xml acrx-20231108_pre.xml acrx20231107_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "acrx20231107_8k.htm": { "nsprefix": "acrx", "nsuri": "http://www.acrx.com/20231108", "dts": { "schema": { "local": [ "acrx-20231108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "acrx-20231108_def.xml" ] }, "labelLink": { "local": [ "acrx-20231108_lab.xml" ] }, "presentationLink": { "local": [ "acrx-20231108_pre.xml" ] }, "inline": { "local": [ "acrx20231107_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.acrx.com/20231108/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20238K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acrx20231107_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20238K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "acrx20231107_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.acrx.com/20231108/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001437749-23-030955-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-030955-xbrl.zip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